International Surgical Outcomes Study Group. Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth. 2016;117:601–9.
Fortun J, Martin-Davila P, Pascual J, Cervera C, Moreno A, Gavalda J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis. 2010;12:397–405.
van Kooten RT, Bahadoer RR, Peeters K, Hoeksema JHL, Steyerberg EW, Hartgrink HH, et al. Preoperative risk factors for major postoperative complications after complex gastrointestinal cancer surgery: a systematic review. Eur J Surg Oncol. 2021;47:3049–58.
Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251:807–18.
Kurita N, Miyata H, Gotoh M, Shimada M, Imura S, Kimura W, et al. Risk model for distal gastrectomy when treating gastric cancer on the basis of data from 33,917 Japanese patients collected using a nationwide web-based data entry system. Ann Surg. 2015;262:295–303.
Smits FJ, Verweij ME, Daamen LA, van Werkhoven CH, Goense L, Besselink MG, et al. Impact of complications after pancreatoduodenectomy on mortality, organ failure, hospital stay, and readmission: analysis of a nationwide audit. Ann Surg. 2022;275:e222–e8.
Baiocchi GL, Giacopuzzi S, Reim D, Piessen G, Costa PMD, Reynolds JV, et al. Incidence and grading of complications after gastrectomy for cancer using the GASTRODATA registry: a European retrospective observational study. Ann Surg. 2020;272:807–13.
WHO. Guidelines for Safe Surgery 2009: Safe Surgery Saves Lives. Geneva; 2009.
Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6:86.
Andersson R, Andersson B, Andersson E, Eckerwall G, Norden M, Tingstedt B. Immunomodulation in surgical practice. HPB (Oxf). 2006;8:116–23.
Adiamah A, Skorepa P, Weimann A, Lobo DN. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. Ann Surg. 2019;270:247–56.
Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8.
Hernandez R, Poder J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22:614–28.
Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–32.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019;30:1902–13.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
National Institute for Health and Care Excellence. NICE guidance “Conditions and diseases” United Kingdom 2025 [cited 31 January 2025]. Available from: https://www.nice.org.uk/guidance/conditions-and-diseases.
US Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 2017, November 27. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 [cited 20th February 2025].
Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.cochrane.org/handbook.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol. 2011;64:1277–82.
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.
J. Sweeting M, J. Sutton A, C. Lambert P. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–75.
Angelini C, Bovo G, Muselli P, Mussi C, Crippa S, Caprotti R, et al. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results. Hepato Gastroenterol. 2006;53:141–4.
Brivio F, Fumagalli L, Lissoni P, Nardone A, Nespoli L, Fattori L, et al. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C. Anticancer Res. 2006;26:599–603.
Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology. 1996;53:263–8.
Brivio F, Lissoni P, Gilardi R, Ferrante R, Vigore L, Curzi L, et al. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients. J Biol Regul Homeost Agents. 2000;14:200–3.
Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, et al. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology. 1992;49:215–8.
Brivio F, Lissoni P, Perego MS, Lissoni A, Fumagalli L. Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications. J Biol Regul Homeost Agents. 2001;15:370–4.
Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, et al. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol. 2007;14:1295–304.
Deehan DJ, Heys SD, Ashby J, Eremin O. Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol. 1995;21:16–22.
Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, et al. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Homeost Agents. 1995;9:31–3.
Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res. 1992;52:5765–9.
Romano F, Cesana G, Caprotti R, Bovo G, Uggeri F, Piacentini MG, et al. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients. Hepato Gastroenterol. 2006;53:634–8.
Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, et al. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol. 2004;88:240–7.
Uggeri F, Caprotti R, De Grate L, Crippa S, Nobili C, Penati C, et al. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. Hepato Gastroenterol. 2009;56:861–5.
Konrad MWHG, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, Bradley EC. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990;50:2009–17.
Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28:109–23.
Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10:199–223.
Tai LH, Tanese de Souza C, Sahi S, Zhang J, Alkayyal AA, Ananth AA, et al. A mouse tumor model of surgical stress to explore the mechanisms of postoperative immunosuppression and evaluate novel perioperative immunotherapies. J Vis Exp. 2014:e51253. https://doi.org/10.3791/51253.
Chiarello MM, Fransvea P, Cariati M, Adams NJ, Bianchi V, Brisinda G. Anastomotic leakage in colorectal cancer surgery. Surg Oncol. 2022;40:101708.
Tsujimoto H, Kobayashi M, Sugasawa H, Ono S, Kishi Y, Ueno H. Potential mechanisms of tumor progression associated with postoperative infectious complications. Cancer Metastasis Rev. 2021;40:285–96.
Coccolini F, Improta M, Cicuttin E, Catena F, Sartelli M, Bova R, et al. Surgical site infection prevention and management in immunocompromised patients: a systematic review of the literature. World J Emerg Surg. 2021;16:33.
Stevens NE, Chapman MJ, Fraser CK, Kuchel TR, Hayball JD, Diener KR. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci Rep. 2017;7:5850.
Zhang Y, Rajput A, Jin N, Wang J. Mechanisms of immunosuppression in colorectal cancer. Cancers. 2020;12:3850.
Bezu L, Akçal Öksüz D, Bell M, Buggy D, Diaz-Cambronero O, Enlund M, et al. Perioperative immunosuppressive factors during cancer surgery: an updated review. Cancers. 2024;16:2304.
Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293–301.
Kazaure HS, Roman SA, Sosa JA. Association of postdischarge complications with reoperation and mortality in general surgery. Arch Surg. 2012;147:1000–7.
Selby LV, Gennarelli RL, Schnorr GC, Solomon SB, Schattner MA, Elkin EB, et al. Association of hospital costs with complications following total gastrectomy for gastric adenocarcinoma. JAMA Surg. 2017;152:953–8.
Klatte T, Ittenson A, Rohl FW, Ecke M, Allhoff EP, Bohm M. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer. 2006;95:1167–73.
Handke J, Kummer L, Weigand MA, Larmann J. Modulation of peripheral CD4(+)CD25(+)Foxp3(+) regulatory T cells ameliorates surgical stress-induced atherosclerotic plaque progression in ApoE-deficient mice. Front Cardiovasc Med. 2021;8:682458.
Scholz AS, Handke J, Gillmann HJ, Zhang Q, Dehne S, Janssen H, et al. Frontline Science: low regulatory T cells predict perioperative major adverse cardiovascular and cerebrovascular events after noncardiac surgery. J Leukoc Biol. 2020;107:717–30.
Davey Smith G, Egger M, Phillips AN. Meta-analysis. Beyond the grand mean? BMJ. 1997;315:1610–4.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12.